Shares of Haemonetics (HAE) have gained 2.4% over the past four weeks to close the last trading session at $86.20, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of$112.17 indicates a potential upside of 30.1%.The average comprises six short-term price targets ranging from a low of $94 to a high of$125, with a standard deviation of $10.87. While the lowest estimate indicates an ...